Bristol-Myers Squibb Company stock page - price, fundamentals, dividends - iOCharts

BMY

64.89
-0.04 (-0.06%)
Bristol-Myers Squibb Company (NYSE, USD)
Healthcare >
Drug Manufacturers-General
Market cap
144.03B
Ent value
204.10B
Price/Sales
3.39
Price/Book
3.86
Div yield
3.02%
Div growth
5.22%
Growth years
12
FCF payout
30.64%
Trailing P/E
-
Forward P/E
8.29
PEG
-
EPS growth
10.90%
1 year return
-2.77%
3 year return
9.37%
5 year return
2.89%
10 year return
6.64%
Last updated: 2022-01-19

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open64.68
Daily high65.03
Daily low63.81
Daily Volume10.5M
All-time high76.77
1y analyst estimate72.76
Beta0.59
EPS (TTM)-4.06
Dividend per share1.96
Ex-div date6 Jan 2022
Next earnings date27 Oct 2021

Downside potential

Loading...
Downside potential data
BMYS&P500
Current price drop from All-time high-15.47%-4.44%
Highest price drop-76.73%-56.47%
Date of highest drop16 Oct 20089 Mar 2009
Avg drop from high-35.09%-11.36%
Avg time to new high41 days12 days
Max time to new high4176 days1805 days

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share1.96
Dividend yield3.02%
Payout frequencyQuarterly
Maximum yield3.88%
Average yield3.02%
Minimum yield2.32%
Discount to avg yield0.01%
Upside potential0.01%
Yield as % of max yield77.86%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield3.02%
Current yield distribution50.48%
Yield at 100% (Min)2.32%
Yield at 90%2.59%
Yield at 80%2.75%
Yield at 50% (Median)3.02%
Yield at 20%3.28%
Yield at 10%3.44%
Yield at 0% (Max)3.88%

Dividend per share

Loading...
Dividend per share data
Years of growth12 years
CCC statusDividend Contender
Dividend per share1.96
Payout frequencyQuarterly
Ex-div date6 Jan 2022
EPS (TTM)-4.06
EPS (1y forward)7.83
EPS growth (5y)10.90%
EPS growth (5y forward)18.40%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
BMYS&P500
DGR MR10.20%14.59%
DGR TTM9.24%0.48%
DGR 3 years-2.79%3.88%
DGR 5 years5.22%4.73%
DGR 10 years1.08%8.30%
DGR 15 years1.83%5.82%
Time since last change announced38 days
EPS growth (5y)10.90%
EPS growth (5y forward)18.40%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM-45.20%30.64%
Average--
Forward25.03%-

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF10.25
Price to FCF10.83
Price to EBITDA41.05
EV to EBITDA58.17

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales3.39
Price to Book3.86
EV to Sales4.80

FINANCIALS

Per share

Loading...
Per share data
Current share count2.22B
EPS (TTM)-4.06
FCF per share (TTM)5.99

Income statement

Loading...
Income statement data
Revenue (TTM)42.52B
Gross profit (TTM)30.75B
Operating income (TTM)2.18B
Net income (TTM)-9.02B
EPS (TTM)-4.06
EPS (1y forward)7.83

Margins

Loading...
Margins data
Gross margin (TTM)72.31%
Operating margin (TTM)5.12%
Profit margin (TTM)-21.20%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash13.54B
Net receivables11.74B
Total current assets31.44B
Goodwill20.52B
Intangible assets44.93B
Property, plant and equipment0.00
Total assets110.89B
Accounts payable2.69B
Short/Current long term debt45.84B
Total current liabilities21.46B
Total liabilities73.61B
Shareholder's equity37.28B
Net tangible assets-28.24B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)14.05B
Capital expenditures (TTM)753.00M
Free cash flow (TTM)13.30B
Dividends paid (TTM)4.08B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-23.80%
Return on Assets-7.61%
Return on Invested Capital-10.18%
Cash Return on Invested Capital15.02%
COMPANY DETAILS
BMY (Bristol-Myers Squibb Company) company logo
Marketcap
144.03B
Marketcap category
Large-cap
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; Huyabio; DarwinHealth, Inc; and Bolt Biotherapeutics, Inc. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Employees
30250
SEC filings
CEO
Giovanni Caforio
Country
USA
City
New York
Stock type
Common stock
CCC status
Dividend Contender
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Investment company Traverso Chambers Private Wealth Management, LLC (Current Portfolio) buys WisdomTree U.S.
January 19, 2022
Investment company Community Capital Management, LLC (Current Portfolio) buys Fidelity National Financial Inc, Quanta Services Inc, Global Payments Inc, AmerisourceBergen Corp, Jack In The Box Inc, se...
January 19, 2022
Investment company St Denis J Villere & Co LLC (Current Portfolio) buys Bank of America Corp, Paya Holdings Inc, Open Lending Corp, Verizon Communications Inc, Newell Brands Inc, sells eHealth Inc, Ab...
January 19, 2022
Mequon, WI, based Investment company A. D. Beadell Investment Counsel, Inc. (Current Portfolio) buys Intellicheck Inc, Primoris Services Corp, Kinder Morgan Inc, Merck Inc, NXP Semiconductors NV, sell...
January 19, 2022
Investment company Tnf Llc (Current Portfolio) buys Vanguard Growth ETF, ConocoPhillips, Bristol-Myers Squibb Co, Northrop Grumman Corp, BCE Inc, sells Virtus AllianzGI Equitynvertible Income Fund dur...
January 18, 2022
Stockholm, V7, based Investment company HealthInvest Partners AB (Current Portfolio) buys McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp, Bristol-Myers Squibb Co, AbbVie Inc, sells Supernu...
January 18, 2022
In this article, we discuss the 11 best blue chip stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Blue Chip Stocks To Buy Now. Newly released da...
January 18, 2022
Westport, CT, based Investment company Gilman Hill Asset Management, LLC (Current Portfolio) buys Star Bulk Carriers Corp, The Western Union Co, JetBlue Airways Corp, Clearway Energy Inc, Bristol-Myer...
January 18, 2022
A long-standing commitment to public-private partnerships offer an example to countries about the possibilities of treating deadly diseases.
January 18, 2022
Investment company Relyea Zuckerberg Hanson LLC (Current Portfolio) buys Marsh & McLennan Inc, Colgate-Palmolive Co, iShares MSCI ACWI Low Carbon Target ETF, Oracle Corp, Bristol-Myers Squibb Co, sell...
January 14, 2022
Next page